Document:

Exhibit 10.23

 

NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH
EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

Axxess
pharma, inc.

 

	Warrant Shares: 1,000,000	Issue Date:  November 4, 2014

 

THIS COMMON STOCK PURCHASE
WARRANT (the “Warrant”) certifies that, for value received, WHC Capital, LLC or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or prior to the close of business on November 4, 2017 (the “Termination Date”) but not thereafter, to subscribe
for and purchase from Axxess Pharma, Inc., a Nevada corporation (the “Company”), up to 1,000,000 shares (as
subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.          Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the “Agreement”), dated November 4, 2014, among the Company and the Holder.

 

    	1

    	 

    

 

Section 2.              Exercise.

 

a)            Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed
facsimile copy of the Notice of Exercise in the form annexed hereto and within three (3) Trading Days of the date said Notice of
Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price of the shares thereby
purchased by wire transfer or cashier’s check drawn on a United States bank. No ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which
case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final
Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total
number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.

 

b)           Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $0.25535, subject to adjustment hereunder
(the “Exercise Price”).

 

		c)	Mechanics of Exercise.

 

i.            Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be issued by the Transfer Agent to the Holder.

 

ii.         Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.         No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.

 

    	2

    	 

    

 

iv.         Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Transfer Agent fees required for processing of any Notice of Exercise.

 

d)          Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below).  The “Beneficial Ownership Limitation” shall be
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section 2(d), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(d) shall continue
to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the
Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

Section 3.          Certain
Adjustments.

 

a)        Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

    	3

    	 

    

 

b)           Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

c)           Notice
to Holder.

 

i.            Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii.         Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer
of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the
date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall
not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise
this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.

 

    	4

    	 

    

 

Section 4.          Transfer
of Warrant.

 

a)        Transferability.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the
Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3)
Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having
a new Warrant issued.

 

b)        New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue
Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)        Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

    	5

    	 

    

 

d)        Transfer
Restrictions. If, at the time
of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either
(i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible
for resale pursuant to Rule 144.

 

e)        Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.

 

Section 5.          Miscellaneous.

 

a)        No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2, except as expressly set forth in Section
3.

 

b)        Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)        Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
Business Day.

 

    	6

    	 

    

 

d)        Authorized
Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e)           Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Agreement.

 

f)            Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of
this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.

 

    	7

    	 

    

 

g)        Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Agreement.

 

h)        Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.

 

i)         Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

j)         Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.

 

k)        Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

l)         Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

m)        Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

[Signature Page Follows]

 

    	8

    	 

    

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

  

	 	axxess pharma, Inc.
	 	 
	 	By: 	/s/ Peter Daniel Bagi
	 	 	Name: /s/ Peter Daniel Bagi
	 	 	Title: Chief Executive Officer

 

    	9

    	 

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

		To:	axxess pharma,
inc.

 

(1)  The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.

 

(2)  A
total of $_____________ has been wired to the Company.

 

(3)  Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The Warrant Shares shall be delivered to
the following address:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(4) Accredited Investor.
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity:	 

	Signature of Authorized Signatory of Investing Entity:	 

	Name of Authorized Signatory: 	 

	Title of Authorized Signatory: 	 

	Date: 	 

 

    	 

    	 

    

 

EXHIBIT B

 

ASSIGNMENT
FORM

 

(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	 	 
	Address:	 
	 	(Please Print)
	 	 
	Dated: _______________ __, ______	 
	 	 
	Holder’s Signature:______________________	 
	 	 
	Holder’s Address: ______________________Exhibit 10.24

 

STOCK PLEDGE AGREEMENT

 

This STOCK PLEDGE AGREEMENT, dated as of
November 4, 2014 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this“Agreement”),
made by and among Axxess Pharma, Inc., a Nevada corporation (the “Borrower”), the undersigned parties as named
on Schedule 1 hereto (collectively, the “Pledgor”), in favor of WHC Capital LLC (the “Secured Party”).

 

WHEREAS, on the date hereof, the Secured
Party has made loans to the Borrower, evidenced by that certain secured promissory note (as amended, supplemented or otherwise
modified from time to time, the “Loan Agreement”) having a face value of $312,500 (the “Loans”),
of even date herewith, made by the Borrower and payable to the order of the Secured Party. Capitalized terms used but not otherwise
defined herein shall have the meanings assigned to such terms in the Loan Agreement.

 

WHEREAS, this Agreement is given by the
Pledgor in favor of the Secured Party to secure the payment and performance of the Secured Obligations; and

 

WHEREAS, it is a condition to the obligations
of the Secured Party to make the Loans under the Loan Agreement that the Pledgor and the Borrower execute and deliver this Agreement.

 

NOW, THEREFORE, in consideration of the
mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:

 

1.     Definitions  

 

(a)  Unless otherwise
specified herein, all references to Sections and Schedules herein are to Sections and Schedules of this Agreement.

 

(b)  Unless otherwise
defined herein, terms used herein that are defined in the UCC shall have the meanings assigned to them in the UCC. However, if
a term is defined in Article 9 of the UCC differently than in another Article of the UCC, the term has the meaning specified in
Article 9.

 

(c)  For purposes of
this Agreement, the following terms shall have the following meanings:

 

“Average Daily Trading
Volume” means the average trading volume of the common stock of the Borrower of the ten Trading Days prior to the date
of an Event of Default under the Loan Agreement.

 

“Closing Price”
means on any given Trading Day, the closing price (as reported by a direct feed service) of the common stock of the Borrower
on the Principal Market or, if the Common Stock is not traded on a Principal Market, the highest reported closing price for the
common stock of the Borrower, as made available through FINRA.

 

“Collateral” has
the meaning set forth in Section 2.

 

“Event of Default” has
the meaning set forth in the Loan Agreement.

 

    	 

    	 

    

 

“Pledged Shares” means
the shares of stock described in Schedule 1 hereto and issued by the Borrower to the Pledgor, and the certificates, instruments
and agreements representing the Pledged Shares and includes any securities or other interests, howsoever evidenced or denominated,
received by the Pledgor in exchange for or as a dividend or distribution on or otherwise received in respect of the Pledged Shares.

 

“Principal Market”
means as of any given date, whichever of the New York Stock Exchange, the Nasdaq Global Select Market, the Nasdaq Global Market,
the Nasdaq Capital Market, the American Stock Exchange, the OTCBB, the OTCQB, or the OTCPink is at the time the principal trading
exchange or market for the common stock of the Borrower.

 

“Proceeds” means
“proceeds” as such term is defined in Section 9-102 of the UCC and, in any event, shall include, without limitation,
all dividends or other income from the Pledged Shares, collections thereon or distributions with respect thereto.

 

“Secured Obligations” has
the meaning set forth in Section 3.

 

“Trading Day”
shall mean any day during which the New York Stock Exchange shall be open for business.

 

“UCC” means
the Uniform Commercial Code as in effect from time to time in the State of New York or, when the laws of any other state govern
the method or manner of the perfection or enforcement of any security interest in any of the Collateral, the Uniform Commercial
Code as in effect from time to time in such state.

 

2.     Pledge The Pledgor
hereby pledges, assigns and grants to the Secured Party, and hereby creates a continuing first priority lien and security interest
in favor of the Secured Party in and to all of its right, title and interest in and to the Pledged Shares, wherever located, whether
now existing or hereafter from time to time arising or acquired (collectively, the “Collateral”). Such Collateral
shall be held in the office of Szaferman Lakind Blumstein &Blader, PC, as the escrow agent.

  

3.     Secured Obligations The
Collateral secures the due and prompt payment and performance of:

 

(a)  the obligations
of the Borrower and/or the Pledgor from time to time arising under the Loan Agreement, this Agreement or otherwise with respect
to the due and prompt payment of (i) the principal of, and interest on the Loans (including interest accruing during the pendency
of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding),
when and as due, whether at maturity, by acceleration, upon one or more dates set for prepayment or otherwise and (ii) all other
monetary obligations, including fees, costs, attorneys’ fees and disbursements, reimbursement obligations, contract causes
of action, expenses and indemnities, whether primary, secondary, direct or indirect, absolute or contingent, due or to become due,
now existing or hereafter arising, fixed or otherwise (including monetary obligations incurred during the pendency of any bankruptcy,
insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), of the Borrower
and/or the Pledgor under or in respect of the Loan Agreement and this Agreement; and

 

    	2

    	 

    

 

(b)  all other covenants,
duties, debts, obligations and liabilities of any kind of the Borrower and/or the Pledgor under or in respect of the Loan Agreement,
this Agreement or any other document made, delivered or given in connection with any of the foregoing, in each case whether evidenced
by a note or other writing, whether allowed in any bankruptcy, insolvency, receivership or other similar proceeding, whether arising
from an extension of credit, issuance of a letter of credit, acceptance, loan, guaranty, indemnification or otherwise, and whether
primary, secondary, direct or indirect, absolute or contingent, due or to become due, now existing or hereafter arising, fixed
or otherwise (all such obligations, covenants, duties, debts, liabilities, sums and expenses set forth in Section 3 being herein
collectively called the ”Secured Obligations”).

 

4.     Representations
and Warranties The Pledgor and the Borrower, as applicable, represent and warrant as follows:

 

(a)  The Pledged Shares
have been duly authorized and validly issued, and are fully paid and non-assessable and subject to no options to purchase or similar
rights.

 

(b)  At the time the
Collateral becomes subject to the lien and security interest created by this Agreement, the Pledgor will be the sole, direct, legal
and beneficial owner thereof, free and clear of any lien, security interest, encumbrance, claim, option or right of others except
for the security interest created by this Agreement.

 

(c)  The pledge of the
Collateral pursuant to this Agreement creates a valid and perfected first priority security interest in the Collateral.

 

(d)  The Borrower has
full power, authority and legal right to borrow the Loans and the Pledgor has full power, authority and legal right to pledge the
Collateral pursuant to this Agreement.

 

(e)  Each of this Agreement
and the Loan Agreement has been duly authorized, executed and delivered by the Borrower and the Pledgor and constitutes a legal,
valid and binding obligation of the Borrower and the Pledgor enforceable in accordance with its terms, subject to applicable bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and subject to equitable
principles (regardless of whether enforcement is sought in equity or at law).

 

(f)  No authorization,
approval, or other action by, and no notice to or filing with, any governmental authority, regulatory body or any other entity
is required for the borrowing of the Loans and the pledge by the Pledgor of the Collateral pursuant to this Agreement or for the
execution and delivery of the Loan Agreement and this Agreement by the Borrower and the Pledgor or the performance by the Borrower
and/or Pledgor of its respective obligations thereunder and hereunder.

 

(g)  The execution and
delivery of the Loan Agreement and this Agreement by the Borrower and the Pledgor and the performance by the Borrower and the Pledgor
of their respective obligations thereunder, will not violate any provision of any applicable law or regulation or any order, judgment,
writ, award or decree of any court, arbitrator or governmental authority, domestic or foreign, applicable to the Borrower or the
Pledgor, as applicable, or any of their respective property, or the organizational or governing documents of the Borrower or any
agreement or instrument to which the Borrower or the Pledgor is party or by which it or its property is bound.

 

    	3

    	 

    

 

5.     Dividends and Voting
Rights  

 

(a)  The Secured Party
agrees that unless an Event of Default shall have occurred, the Pledgor may, to the extent the Pledgor has such right as a holder
of the Pledged Shares, vote and give consents, ratifications and waivers with respect thereto, except to the extent that, in the
Secured Party’s reasonable judgment, any such vote, consent, ratification or waiver would detract from the value thereof
as Collateral or which would be inconsistent with or result in any violation of any provision of the Loan Agreement or this Agreement.

 

(b)  The Secured Party
agrees that the Pledgor may, unless an Event of Default shall have occurred, receive and retain all cash dividends and other distributions
with respect to the Pledged Shares.

 

6.     Further Assurances  

 

(a)  The Pledgor shall,
at its own cost and expense, defend title to the Collateral and the first priority lien and security interest of the Secured Party
therein against the claim of any person claiming against or through the Pledgor and shall maintain and preserve such perfected
first priority security interest for so long as this Agreement shall remain in effect.

 

(b)  The Pledgor agrees
that at any time and from time to time, at the expense of the Pledgor, the Pledgor will promptly execute and deliver all further
instruments and documents, obtain such agreements from third parties, and take all further action, that may be necessary or desirable,
or that the Secured Party may reasonably request, in order to perfect and protect any security interest granted hereby or to enable
the Secured Party to exercise and enforce its rights and remedies hereunder or under any other agreement with respect to any Collateral.

 

(c)  The Pledgor will
not, without providing at least 30 days’ prior written notice to the Secured Party, change its legal name or identity. The
Pledgor will, prior to any change described in the preceding sentence, take all actions reasonably requested by the Secured Party
to maintain the perfection and priority of the Secured Party’s security interest in the Collateral.

 

7.     Transfers and Other Liens  The
Pledgor agrees that it will not sell, offer to sell, dispose of, convey, assign or otherwise transfer, grant any option with respect
to, restrict, or grant, create, permit or suffer to exist any mortgage, pledge, lien, security interest, option, right of first
offer, encumbrance or other restriction or limitation of any nature whatsoever on, any of the Collateral or any interest therein
except as expressly provided for herein or with the prior written consent of the Secured Party.

 

8.    Secured Party Appointed
Attorney-in-Fact  The Pledgor hereby appoints the Secured Party the Pledgor’s attorney-in-fact, with full authority
in the place and stead of the Pledgor and in the name of the Pledgor or otherwise, from time to time during the continuance of
an Event of Default in the Secured Party’s discretion to take any action and to execute any instrument which the Secured
Party may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, to receive,
endorse and collect all instruments made payable to the Pledgor representing any dividend, interest payment or other distribution
in respect of the Collateral or any part thereof and to give full discharge for the same (but the Secured Party shall not be obligated
to and shall have no liability to the Pledgor or any third party for failure to do so or take action). Such appointment, being
coupled with an interest, shall be irrevocable. The Pledgor hereby ratifies all that said attorneys-in-fact shall lawfully do or
cause to be done by virtue hereof.

 

    	4

    	 

    

 

9.   Secured Party May Perform If
the Pledgor fails to perform any obligation contained in this Agreement, the Secured Party may itself perform, or cause performance
of, such obligation, and the expenses of the Secured Party incurred in connection therewith shall be payable by the Pledgor; provided
that the Secured Party shall not be required to perform or discharge any obligation of the Pledgor.

 

10.    Reasonable Care The
Secured Party shall have no duty with respect to the care and preservation of the Collateral beyond the exercise of reasonable
care, and as further described below. The Secured Party shall be deemed to have exercised reasonable care in the custody and preservation
of the Collateral in its possession if the Collateral is accorded treatment substantially equal to that which the Secured Party
accords its own property, it being understood that the Secured Party shall not have any responsibility for (a) ascertaining or
taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Collateral, whether
or not the Secured Party has or is deemed to have knowledge of such matters, or (b) taking any necessary steps to preserve rights
against any parties with respect to any Collateral. Nothing set forth in this Agreement, nor the exercise by the Secured Party
of any of the rights and remedies hereunder, shall relieve the Pledgor from the performance of any obligation on the Pledgor’s
part to be performed or observed in respect of any of the Collateral.

 

11.    Remedies Upon Default If
any Event of Default shall have occurred:

 

(a)  The Secured Party
may, without any other notice to or demand upon the Pledgor, assert all rights and remedies of a secured party under the UCC or
other applicable law, including, without limitation, the right to take possession of, hold, collect, sell, lease, deliver, grant
options to purchase or otherwise retain, liquidate or dispose of all or any portion of the Collateral. If notice prior to disposition
of the Collateral or any portion thereof is necessary under applicable law, written notice mailed to the Pledgor at its notice
address as provided in Section 16 hereof ten days prior to the date of such disposition shall constitute reasonable notice, but
notice given in any other reasonable manner shall be sufficient. So long as the sale of the Collateral is made in a commercially
reasonable manner and in accordance with Section 12 below, the Secured Party may sell such Collateral on such terms and to such
purchaser(s) as the Secured Party in its absolute discretion may choose, without assuming any credit risk and without any obligation
to advertise or give notice of any kind other than that necessary under applicable law. Without precluding any other methods of
sale, the sale of the Collateral or any portion thereof shall have been made in a commercially reasonable manner if conducted in
conformity with reasonable commercial practices of creditors disposing of similar property. At any sale of the Collateral, if permitted
by applicable law, the Secured Party may be the purchaser, licensee, assignee or recipient of the Collateral or any part thereof
and shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion
of the Collateral sold, assigned or licensed at such sale, to use and apply any of the Secured Obligations as a credit on account
of the purchase price of the Collateral or any part thereof payable at such sale. To the extent permitted by applicable law, the
Pledgor waives all claims, damages and demands it may acquire against the Secured Party arising out of the exercise by it of any
rights hereunder. The Pledgor hereby waives and releases to the fullest extent permitted by law any right or equity of redemption
with respect to the Collateral, whether before or after sale hereunder, and all rights, if any, of marshalling the Collateral and
any other security for the Secured Obligations or otherwise. At any such sale, unless prohibited by applicable law, the Secured
Party or any custodian may bid for and purchase all or any part of the Collateral so sold free from any such right or equity of
redemption. Neither the Secured Party nor any custodian shall be liable for failure to collect or realize upon any or all of the
Collateral or for any delay in so doing, nor shall it be under any obligation to take any action whatsoever with regard thereto.
The Secured Party shall not be obligated to clean-up or otherwise prepare the Collateral for sale.

 

    	5

    	 

    

 

(b)  If the Secured
Party shall determine to exercise its rights to sell all or any of the Collateral pursuant to this Section, the Pledgor agrees
that, upon request of the Secured Party, the Pledgor will, at its own expense, do or cause to be done all such acts and things
as may be necessary to make such sale of the Collateral or any part thereof valid and binding and in compliance with applicable
law.

 

12.    Omitted.

 

13.    No Waiver and Cumulative
Remedies  The Secured Party shall not by any act (except by a written instrument pursuant to Section 15), delay,
indulgence, omission or otherwise be deemed to have waived any right or remedy hereunder or to have acquiesced in any Event of
Default. All rights and remedies herein provided are cumulative and are not exclusive of any rights or remedies provided by law.

 

14.    Security Interest Absolute  The
Pledgor hereby waives demand, notice, protest, notice of acceptance of this Agreement, notice of loans made, credit extended, Collateral
received or delivered or other action taken in reliance hereon and all other demands and notices of any description. All rights
of the Secured Party and liens and security interests hereunder, and all Secured Obligations of the Pledgor hereunder, shall be
absolute and unconditional irrespective of:

 

(a)  any illegality
or lack of validity or enforceability of any Secured Obligation or any related agreement or instrument;

 

(b)  any taking, exchange,
substitution, release, impairment or non-perfection of any Collateral, or any taking, release, impairment, amendment, waiver or
other modification of any guaranty, for all or any of the Secured Obligations;

 

(c)  any default,
failure or delay, willful or otherwise, in the performance of the Secured Obligations;

 

(d)  any defense,
set-off or counterclaim (other than a defense of payment or performance) that may at any time be available to, or be asserted by,
the Pledgor against the Secured Party; or

 

(e)  any other circumstance
(including, without limitation, any statute of limitations) or manner of administering the Loans or any existence of or reliance
on any representation by the Secured Party that might vary the risk of the Pledgor or otherwise operate as a defense available
to, or a legal or equitable discharge of, the Pledgor or any other grantor, guarantor or surety.

 

15.    Amendments None of
the terms or provisions of this Agreement may be amended, modified, supplemented, terminated or waived, and no consent to any departure
by the Pledgor therefrom shall be effective unless the same shall be in writing and signed by the Secured Party and the Pledgor,
and then such amendment, modification, supplement, waiver or consent shall be effective only in the specific instance and for the
specific purpose for which made or given.

 

16.     Addresses For Notices All
notices and other communications provided for in this Agreement shall be in writing and shall be given in the manner and become
effective as set forth in the Loan Agreement, and addressed to the respective parties at their addresses as specified on the signature
pages hereof or as to either party at such other address as shall be designated by such party in a written notice to each other
party.

 

    	6

    	 

    

 

17.    Continuing Security
Interest; Further Actions  This Agreement shall create a continuing first priority lien and security interest in
the Collateral and shall (a) subject to Section 18, remain in full force and effect until payment and performance in full of the
Secured Obligations, (b) be binding upon the Pledgor, its successors and assigns, and (c) inure to the benefit of the Secured Party
and its successors, transferees and assigns; provided that the Pledgor may not assign or otherwise transfer any of its rights
or obligations under this Agreement without the prior written consent of the Secured Party.  

 

18.    Termination; Release  On
the date on which all Loans and other Secured Obligations have been paid and performed in full, the Secured Party will, at the
request and sole expense of the Pledgor, (a) duly assign, transfer and deliver to or at the direction of the Pledgor (without recourse
and without any representation or warranty) such of the Collateral as may then remain in the possession of the Secured Party, together
with any monies at the time held by the Secured Party hereunder, and (b) execute and deliver to the Pledgor a proper instrument
or instruments acknowledging the satisfaction and termination of this Agreement.

 

19.    GOVERNING LAW This
Agreement and the Loan Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise)
based upon, arising out of or relating to this Agreement or the Loan Agreement (except, as to the Loan Agreement, as expressly
set forth therein) and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with,
the laws of the State of New York. 

 

20.    Counterparts This
Agreement and any amendments, waivers, consents or supplements hereto may be executed in counterparts (and by different parties
hereto in different counterparts), each of which shall constitute an original, but all taken together shall constitute a single
contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., “pdf”
or “tif”) format shall be effective as delivery of a manually executed counterpart of this Agreement. This Agreement
and the Loan Agreement constitute the entire contract among the parties with respect to the subject matter hereof and supersede
all previous agreements and understandings, oral or written, with respect thereto.

 

    	7

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the date first above written.

 

	 	Axxess Pharma, Inc., as Borrower
	 	 	 
	 	By:	/s/ Peter Daniel Bagi
	 	Name: Peter Daniel Bagi
	 	Title:  Chief Executive Officer
	 	Address for Notices:
	 	 
	 	Peter Daniel Bagi, as Pledgor
	 	 	 
	 	By:	/s/ Peter Daniel Bagi
	 	Name: Peter Daniel Bagi
	 	Address for Notices:
	 	 
	 	WHC Capital LLC, as Secured Party
	 	 	 
	 	By	/s/ Hamin Abdullah
	 	Name: Hamin Abdullah
	 	Title: President
	 	Address for Notices:

 

    	8

    	 

    

 

SCHEDULE 1

PLEDGED SHARES

 

	Pledgor	 	Pledged Shares	 
	Peter Daniel Bagi	 	 	3,500,000	 
	 	 	 	 	 
	Total Pledged Shares:	 	 	3,500,000	 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]